Form 4: Sutro Biopharma Director Acquires Stock Options

James P. Panek, a Director at Sutro Biopharma, Inc., acquired 10,000 stock options with an exercise price of $26.09.

Summary

• Director James P. Panek acquired 10,000 stock options for Sutro Biopharma, Inc. (STRO) on June 5, 2026.
• The options have an exercise price of $26.09 and an expiration date of June 5, 2036.
• These options are subject to vesting, with 8.33% vesting monthly, starting July 5, 2026, and full vesting by June 5, 2027, or the 2027 annual stockholders meeting, whichever comes first.
• Following this transaction, Panek beneficially owns 10,000 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates director confidence through option acquisition, but provides no new financial or strategic information.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The exercise price of $26.09 suggests a valuation at or above the current market price at the time of grant.
• The vesting schedule aligns with continued service, incentivizing long-term commitment from the director.

Negatives

• The filing only details the acquisition of options, not the underlying rationale or current financial performance of the company.
• The options are not yet vested, meaning the director does not yet have immediate control over these shares.

Risks

• The value of the stock options is contingent on the future performance of Sutro Biopharma's stock price.
• If the company's stock price does not exceed the exercise price of $26.09, the options may expire worthless.
• Vesting is subject to continued service, meaning any departure from the company before full vesting would result in forfeiture of unvested options.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future stock performance, as the options are only valuable if the stock price increases above the exercise price.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biopharmaceutical industry to incentivize leadership and align their interests with shareholders, particularly during periods of development and potential growth.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively, suggesting confidence in future stock appreciation. However, it does not directly impact current share value or ownership.
• Employees: The vesting schedule for the director's options is tied to continued service, reinforcing the importance of employee retention and performance.
• Management: The transaction aligns the director's financial interests with the company's stock performance.

Next Steps

• Vesting of stock options on a monthly basis starting July 5, 2026.
• Full vesting of stock options by June 5, 2027, or the 2027 annual stockholders meeting.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Insider Trading, Equity Award